|
MechanismCDK7 gene inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
100 Clinical Results associated with EOC Biopharma (Shanghai) Co., Ltd.
0 Patents (Medical) associated with EOC Biopharma (Shanghai) Co., Ltd.
100 Deals associated with EOC Biopharma (Shanghai) Co., Ltd.
100 Translational Medicine associated with EOC Biopharma (Shanghai) Co., Ltd.